Qiagen NV
$ 48.50
2.21%
24 Feb - close price
- Market Cap 9,778,256,000 USD
- Current Price $ 48.50
- High / Low $ 48.69 / 47.80
- Stock P/E 23.26
- Book Value 18.33
- EPS 2.04
- Next Earning Report 2026-05-06
- Dividend Per Share $0.26
- Dividend Yield 0.54 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.12 %
- 52 Week High 57.82
- 52 Week Low 35.53
About
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Analyst Target Price
$55.23
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-04 | 2025-08-05 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-07-30 | 2024-04-28 | 2024-02-05 | 2023-10-30 | 2023-08-08 | 2023-05-02 |
| Reported EPS | 0.62 | 0.64 | 0.63 | 0.58 | 0.64 | 0.62 | 0.6 | 0.5 | 0.6 | 0.56 | 0.57 | 0.57 |
| Estimated EPS | 0.62 | 0.62 | 0.63 | 0.54 | 0.65 | 0.59 | 0.56 | 0.47 | 0.6 | 0.54 | 0.56 | 0.51 |
| Surprise | 0 | 0.02 | 0 | 0.04 | -0.01 | 0.03 | 0.04 | 0.03 | 0 | 0.02 | 0.01 | 0.06 |
| Surprise Percentage | 0% | 3.2258% | 0% | 7.4074% | -1.5385% | 5.0847% | 7.1429% | 6.383% | 0% | 3.7037% | 1.7857% | 11.7647% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.54 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jul 2025 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|
| Payment Date | None | 2025-07-10 | None | None |
| Amount | $2.29 | $0.25 | $1.32 | $1.04 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QGEN
2026-02-21 18:40:23
Jefferies analyst Tycho Peterson has reiterated a Buy rating for Qiagen NV (QGEN.US) and maintained a target price of $59. According to TipRanks data, Peterson has a 57.2% success rate and an average return of 8.9% over the past year. This information is provided for informational purposes only and is not an investment recommendation.
2026-02-21 02:36:48
This article provides an analysis of QIAGEN N.V. (NYSE:QGEN), including its stock price, technical and fundamental ratings, financial highlights, and analyst forecasts. The stock's current price is $48.57, with analysts predicting a 12.64% increase over the next year. QIAGEN scored a technical rating of 2/10 and a fundamental rating of 6/10 from ChartMill, with strong profitability but minor concerns regarding financial health.
2026-02-19 19:03:45
Qiagen N.V., a Netherlands-based biotech tools company with a strong US presence, is gaining attention for its role in diagnostics, cancer testing, and infectious disease labs. While not a meme stock, recent analyst updates and commentary highlight its stable cash flows, recurring consumables revenue, and AI-driven lab automation, positioning it as a long-term diagnostics and lab infrastructure play. The company's US-listed shares (QGEN) make it directly accessible to American investors looking for a defensive health-tech investment.
2026-02-19 12:57:50
Parse Biosciences, a QIAGEN company, has launched its new Evercode™ Whole Transcriptome v4 product line, which offers expanded scalability of up to five million cells and 384 samples in a single run. This new chemistry enhances gene detection per cell, reduces sequencing costs, and increases cell recovery by up to 75% through a simplified magnetic bead-based workflow. The Evercode v4 is designed to make single-cell RNA sequencing more accessible and efficient for researchers, enabling higher biological resolution.
2026-02-19 02:44:12
Stifel analyst Daniel Arias has reiterated a "Hold" rating for Qiagen NV (QGEN.US) and increased the target price from $47.37 to $50. This decision is based on TipRanks data, which indicates a 45.7% success rate and a 0.0% average return for the analyst over the past year. The information provided is for informational purposes only and not investment advice.
2026-02-18 21:58:09
BlackRock, Inc. has revealed a substantial shareholding in Qiagen, holding a 10.68% capital interest and 11.80% of voting rights through various subsidiaries and instruments as of February 11, 2026. This significant stake, largely indirect, underscores strong institutional investor interest in Qiagen's equity and hints at BlackRock's potential influence on the company's governance. Qiagen (QGEN) specializes in sample and assay technologies for molecular diagnostics and currently has a Hold rating from analysts with a $50.00 price target.
